{"prompt": "['7.0 TRIAL PROCEDURES', '7.1', 'Trial Procedures', 'The Trial Flow Chart (Section 6.0) summarizes the trial procedures to be performed at each', 'visit. Individual trial procedures are described in detail below. It may be necessary to', 'perform these procedures at unscheduled time points if deemed clinically necessary by the', 'investigator.', 'Furthermore, additional evaluations/testing may be deemed necessary by the Sponsor and/or', 'Merk for reasons related to participant safety. In some cases, such evaluation/testing may be', 'potentially sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations may', 'require that additional informed consent be obtained from the participant. In these cases,', 'such evaluations/testing will be performed in accordance with those regulations.', '7.1.1', 'Administrative Procedures', '7.1.1.1 Informed Consent', 'The Investigator must obtain documented consent from each potential participant prior to', 'participating in a clinical trial. This must be done within 8 weeks of Cycle 1 Day 1.', '7.1.1.1.1 General Informed Consent', \"Consent must be documented by the participant's dated signature or by the participant's\", \"legally acceptable representative's dated signature on a consent form along with the dated\", 'signature of the person conducting the consent discussion.', 'A copy of the signed and dated consent form should be given to the participant before', 'participation in the trial.', 'The initial informed consent form, any subsequent revised written informed consent form', \"and any written information provided to the participant must receive the IRB/ERC's\", 'approval/favorable opinion in advance of use. The participant or his/her legally acceptable', 'representative should be informed in a timely manner if new information becomes available', \"that may be relevant to the participant's willingness to continue participation in the trial. The\", 'communication of this information will be provided and documented via a revised consent', \"form or addendum to the original consent form that captures the participant's dated signature\", \"or by the participant's legally acceptable representative's dated signature.\", 'Specifics about a trial and the trial population will be added to the consent form template at', 'the protocol level.', 'The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations', 'and Sponsor requirements.', '40']['7.1.1.2 Inclusion/Exclusion Criteria', 'All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee', 'to ensure that the participant qualifies for the trial.', '7.1.1.3 Demographics and Medical History', 'Patient demographics and medical history will be obtained by the investigator or qualified', 'designee. Medical history will include all active conditions, and any condition diagnosed', 'within the prior 10 years that are considered to be clinically significant by the Investigator.', '7.1.1.4 Prior and Concomitant Medications Review', '7.1.1.4.1 Prior Medications', 'The investigator or qualified designee will review prior medication use, including any', 'protocol-specified washout requirement, and record prior medication taken by the participant', 'within 28 days before starting the trial. Treatment for the disease for which the participant', 'has enrolled in this study will be recorded separately and not listed as a prior medication.', '7.1.1.4.2 Concomitant Medications', 'The investigator or qualified designee will record medication, if any, taken by the participant', 'during the trial. All medications related to reportable SAEs and ECIs should be recorded as', 'defined in Section 7.2.', '7.1.1.5 Trial compliance', 'Compliance will be assessed by the investigator and/or study personnel at each patient visit', 'and information provided by the patient and/or caregiver (collection of drug diary) will be', 'captured in the Drug Accountability Form (Appendix 6). This information must be captured', 'in the source document at each patient visit. Dose changes and interruptions of study drug', \"must be specifically documented in the patient's CRF.\", '7.1.1.6 Lenvatinib Administration', 'Lenvatinib will be administrated daily during each 21-day cycle and the initiation of Cycle 1', 'Day 1 should align with the first pembrolizumab administration +/- 3 days.', '7.1.1.7 Pembrolizumab Administration', 'Pembrolizumab will be administered on the 1st day of each 21-day cycle for a total of four', 'cycles.', '41']\n\n###\n\n", "completion": "END"}